OBJECTIVES: V116 is a 21-valent pneumococcal conjugate vaccine (PCV) specifically designed for adults. It includes eight unique serotypes (15A, 15C [from de-O-Ac-15B], 16F, 23A, 23B, 24F, 31 and 35B) not covered by any currently licensed pneumococcal vaccine. According to the 2019 European Centre for Disease Prevention and Control data from Spain, the serotypes covered by V116 are responsible for approximately 84% of invasive pneumococcal disease (IPD) in individuals aged 65+, and the unique 8 serotypes were responsible for approximately 24%. This study estimates the potential health and economic impact of vaccination with V116 vs. PCV20 on IPD amongst adults aged 50+ in Spain.

METHODS: A Markov model estimated the lifetime IPD cases, IPD related deaths, and the associated direct medical costs (2023 Euros) among Spanish adults aged 50-64 and 65+ (assuming 2021 population estimates) vaccinating with V116 or PCV20. The same serotype specific vaccine effectiveness, and the same vaccine coverage rates (~41.6%) were assumed for the two vaccines.

RESULTS: In adults aged 50-64, V116 prevented 473 IPD cases and 53 IPD deaths – 28% more than the 369 IPD cases and 41 IPD deaths prevented by PCV20. The averted IPD cases from V116 vaccination resulted in ~€4.8 million reduction in total medical costs–higher than the ~€3.7 million costs averted by PCV20.

In adults aged 65+, V116 prevented 3,572 IPD cases and 880 IPD deaths – 28% more than the 2,782 IPD cases and 685 IPD deaths prevented by PCV20. The averted IPD cases from V116 vaccination resulted in ~€53 million reduction in total medical costs–higher than the ~€41 million costs averted by PCV20

CONCLUSIONS: In both age groups, V116 resulted in a greater reduction of both the health and economic burden associated with IPD, as compared to PCV20.